These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8914087)

  • 21. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations.
    Meissner W; Leblois A; Hansel D; Bioulac B; Gross CE; Benazzouz A; Boraud T
    Brain; 2005 Oct; 128(Pt 10):2372-82. PubMed ID: 16123144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
    Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M
    Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
    Arai N; Isaji M; Kojima M; Mizuta E; Kuno S
    J Neural Transm (Vienna); 1996; 103(11):1307-16. PubMed ID: 9013417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.
    Emborg-Knott ME; Domino EF
    Exp Neurol; 1998 Aug; 152(2):214-20. PubMed ID: 9710520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
    Kurlan R; Kim MH; Gash DM
    Mov Disord; 1991; 6(2):111-8. PubMed ID: 2057003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N; Grégoire L; Bédard PJ; Di Paolo T
    Neurobiol Aging; 2006 Nov; 27(11):1684-93. PubMed ID: 16253392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
    Rupniak NM; Boyce S; Steventon MJ; Iversen SD; Marsden CD
    Ann Neurol; 1992 Jul; 32(1):103-5. PubMed ID: 1642462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
    Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
    Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation.
    Krack P; Benazzouz A; Pollak P; Limousin P; Piallat B; Hoffmann D; Xie J; Benabid AL
    Mov Disord; 1998 Nov; 13(6):907-14. PubMed ID: 9827614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
    Bergman H; Wichmann T; Karmon B; DeLong MR
    J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.